Model List of Essential Medicines

Acetic acid

Section	Indications
Ear, nose and throat medicines [c] ◦ Local > Otological > drops: 2% solution	Infectious diseases of external ear

Acetylsalicylic acid

Section	Indications
Medicines for acute migraine attacks ◦ Oral > Solid: 300 to 500 mg	Migraine
Anti-platelet medicines ◦ Oral > Solid: 100 mg	Acute myocardial infarction Cerebral ischaemic stroke
Medicines for juvenile joint diseases ◦ Local > Rectal > Suppository: 150 mg; 300 mg ◦ Oral > Solid > dispersible tablet: 75 mg; 300 mg; 500 mg ◦ Oral > Solid > tablet: 75 to 500 mg	Mucocutaneous lymph node syndrome Juvenile idiopathic arthritis Acute rheumatic fever without mention of heart involvement
Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs) ◦ Oral > Solid: 100 to 500 mg ◦ Local > Rectal > Suppository: 50 to 150 mg	Pain

Acetylsalicylic acid + atorvastatin + ramipril

Section	Indications
Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease ◦ Oral > Solid > tablet: 100 mg + 20 mg + 2.5 mg; 100 mg + 20 mg + 5 mg; 100 mg + 20 mg + 10 mg; 100 mg + 40 mg + 2.5 mg; 100 mg + 40 mg + 5 mg; 100 mg + 40 mg + 10 mg	Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke

Acetylsalicylic acid + simvastatin + ramipril + atenolol + hydrochlorothiazide

Section	Indications
Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease ◦ Oral > Solid > tablet: 100 mg + 20 mg + 5 mg + 50 mg + 12.5 mg	Atherosclerotic chronic arterial occlusive disease Chronic ischaemic heart disease Cerebral ischaemic stroke

All-trans retinoic acid

Section	Indications
Targeted therapies ◦ Oral > Solid: 10 mg capsule	Acute myeloid leukaemia with recurrent genetic abnormalities

Amoxicillin + clavulanic acid

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection ◦ Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid ◦ Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt) ◦ Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt) ◦ Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)	**First choice** Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Acute sinusitis Other specified pneumonia (Hospital-acquired pneumonia) Chronic obstructive pulmonary disease with acute exacerbation Neutropaenia (low-risk) Peritoneal abscess (mild-moderate) Peritonitis (mild-moderate) Infectious cystitis Bacterial cellulitis, erysipelas or lymphangitis **Second choice** Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Bacterial pneumonia (Community-acquired pneumonia - severe) Bacterial infection of joint Acute otitis media Other specified prophylactic measures Osteomyelitis or osteitis **Other indications** Bacterial infection of unspecified site
Antituberculosis medicines ◦ Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid ◦ Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt) ◦ Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)	Multi-drug resistant Mycobacterium tuberculosis

Ascorbic acid

Section	Indications
Vitamins and minerals ◦ Oral > Solid: 50 mg	Scurvy

Benzoic acid + salicylic acid

Section	Indications
Dermatological medicines > Antifungal medicines ◦ Local > Topical > Cream: 6% + 3% ◦ Local > Topical > Ointment: 6% + 3%	Fungal infection of the skin

Ferrous salt + folic acid

Section	Indications
Antianaemia medicines ◦ Oral > Solid: 60 mg iron + 2.8 mg ◦ Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg	Iron deficiency anaemia Iron deficiency anaemia Spina bifida Clefts of lip, alveolus or palate Anencephaly or similar anomalies

Folic acid

Section	Indications
Antianaemia medicines ◦ Oral > Solid: 400 µg ◦ Oral > Liquid: 1 mg per mL ◦ Oral > Solid: 1 mg tablet; 5 mg tablet	Cephalocele Anencephaly or similar anomalies Spina bifida Folate deficiency anaemia

Hypochlorous acid

Section	Indications
Disinfectants ◦ Solution (aqueous): containing hypochlorous acid ≥ 150 parts per million	Disinfectant, not elsewhere classified
Antiseptics ◦ Solution (aqueous): containing hypochlorous acid ≥ 150 parts per million	Hypochlorite

Meglumine iotroxate

Section	Indications
Diagnostic agents > Radiocontrast media ◦ Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL	X-ray contrast media, iodinated

Nalidixic acid

Section	Indications
Anti-infective medicines ◦ Oral > Solid: 250 mg; 500 mg	Shigella resistant to unspecified antibiotic

P-aminosalicylic acid

Section	Indications
Antituberculosis medicines ◦ Oral > Solid: 4 g granules in sachet	Multi-drug resistant Mycobacterium tuberculosis

Salicylic acid

Section	Indications
Dermatological medicines > Medicines affecting skin differentiation and proliferation ◦ Local > Topical > Solution: 5%	Seborrhoeic dermatitis Psoriasis of unspecified type Ichthyoses

Tranexamic acid

Section	Indications
Other medicines administered to the mother ◦ Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule	Postpartum haemorrhage
Medicines affecting coagulation ◦ Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule	Haemorrhage, not elsewhere classified

Valproic acid (sodium valproate)

Section	Indications
Antiseizure medicines ◦ Oral > Liquid: 200 mg per 5 mL ◦ Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable) ◦ Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 3 mL ampoule	Epilepsy or seizures Status epilepticus
Medicines for bipolar disorders ◦ Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)	Bipolar or related disorders

Zoledronic acid

Section	Indications
Medicines for endocrine disorders ◦ Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle	Osteogenesis imperfecta
Supportive medicines ◦ Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle	Malignant neoplasm metastasis in bone or bone marrow